M42, the Abu Dhabi health company built around artificial intelligence, technology and genomics, has completed a renal care acquisition in Brazil through its subsidiary Diaverum. Gulf Daily News reported that Diaverum has taken over four clinics in the state of Sao Paulo, deepening a network that now reaches across Latin America’s largest healthcare market. The deal moves four established dialysis sites into a single accredited operator, and it fits a wider pattern of cross-border consolidation in chronic renal care.
Diaverum’s Brazil network reaches 18 clinics
The clinics acquired from the Lund Group are CDTR and CDTR Prime in Sorocaba, INDI in Itapetininga, and Lund Nefrologia in Itu. Gulf Daily News reported that these additions take Diaverum’s Brazil network to 18 clinics, including three specialised vascular access centres. That footprint gives Diaverum a broad base across Sao Paulo, and it positions the operator to serve private patients and the public system at the same time. Diaverum’s Brazil expansion is not a single purchase but a run of them, following the earlier acquisition of Servico de Nefrologia Ribeirao Preto. The current transaction also brings management contracts in two public hospitals and a set of acute service agreements, extending renal care delivery across several points in the wider system.
Chronic kidney disease burden in Brazil
Brazil carries a heavy chronic kidney disease burden, with more than 10 million people affected nationwide. The scale is easy to miss. Gulf Daily News reported that many cases go undiagnosed until the advanced stages, when treatment options narrow and the outlook gets worse. In Sao Paulo, the biggest and richest state in Brazil, an estimated 6 per cent to 9 per cent of adults live with chronic kidney disease. Around 2.3 per cent of those adults are at Stage 5, the point at which dialysis becomes a life-sustaining need rather than a choice. That prevalence sets a hard floor under demand for dialysis, and it explains why an operator can absorb four clinics in Sao Paulo and still expect to run near capacity. Demand here is not in doubt.
A scalable dialysis model built for volume
Diaverum’s expanded operations in Brazil are projected to deliver more than 220,000 treatments a year, a figure that tracks the scale of chronic dialysis demand in Sao Paulo. Gulf Daily News reported that the model combines directly owned clinics with public hospital partnerships and acute service agreements. This hybrid structure lets Diaverum serve private and public patients from the same network, and it travels well across health systems that mix state provision with private capacity. The approach reads as an operator backbone rather than a destination brand. That gap matters for how medical tourism actually works. Inbound medical tourism depends on a dense layer of accredited providers running at volume, and renal networks like this one supply exactly that capacity, day in and day out, in a way a single clinic on its own cannot.
Renal networks and continuity of care across borders
Chronic dialysis is one of the few treatments that ties a patient to a chair several times a week, which makes continuity of care the central risk when those patients travel. A single operator running clinics from Abu Dhabi to Sao Paulo can offer something a local clinic cannot, namely portable records and a consistent clinical protocol across borders. For a dialysis patient who wants to travel, the ability to book a compatible session inside the same network removes one of the standard risks of medical travel. That is a narrower and more honest claim than calling Brazil a renal tourism destination, and it is the claim the network structure actually supports. Diaverum’s value here is continuity, not novelty. Continuity is what chronic renal patients pay for.
M42’s cross-border platform ambition
M42 runs its expanding platform from Abu Dhabi and aligns it with data sovereignty rules across each market it enters, according to Gulf Daily News. Dimitris Moulavasilis, group chief executive of M42, framed the Brazil deal as access rather than acquisition, saying it “grants more people in Brazil access to high-quality renal care.” The wider ambition is a connected care platform that carries clinical expertise, digital infrastructure and chronic disease management across several high-growth markets at once. Whether that platform genuinely improves outcomes will show up in Stage 5 detection rates and dialysis continuity, not in the count of clinics acquired. The consolidation logic is sound. The real test is whether scale in Sao Paulo converts into earlier intervention rather than simply more treatments billed.
What the Brazil deal signals
Diaverum’s Brazil expansion reinforces a pattern that has reshaped renal care worldwide, in which a handful of accredited operators absorb independent clinics and run them at scale. For Brazil, more than 10 million people live with chronic kidney disease, and closing the gap between that number and diagnosed, treated cases is the real prize. For medical tourism, the deal matters less as a destination story and more as evidence that the accredited-operator backbone keeps thickening across Latin America. M42 and Diaverum have bought volume and reach in Sao Paulo, and the value of that reach depends on turning undiagnosed chronic kidney disease into earlier, continuous renal care.
